MONDAY, SEPTEMBER 26, 2016

European Medicine Agency reviews HPV vaccine safety profiles

European Medicine Agency reviews HPV vaccine safety profiles. | Courtesy of medicalexpo.com
The European Medicine Agency (EMA) recently began to review human papillomavirus (HPV) vaccines in order to better clarify various points within the vaccines’ safety profiles.

The review is not intended to doubt the benefits of the HPV vaccines, which, according to health professionals, surpass the risks of the vaccine. Rather, the review will study all available data by focusing on rare, specific reports of postural orthostatic tachycardia syndrome (POTS) and complex regional pain syndrome (CRPS).

POTS is a condition that causes the heart rate to rise unusually, especially after standing or sitting up. POTS patients report fainting, dizziness, chest pain, headache and weakness.

CRPS, a chronic pain condition, affects the patients’ limbs.

The review will determine whether the number of women who report having these conditions increases with the administration of the HPV vaccine.

Approximately 72 million people from around the world have used these vaccines. The recipients expect the vaccine to prevent cervical cancer, which is cancer in the neck of the womb, as well as a variety of other conditions and cancers commonly caused by HPV. Currently the fourth most frequent cause of female cancer deaths in the world, countless women die from cervical cancer every year. These deaths occur in spite of existing screen programs that are designed to detect cancer early on.

Organizations in this story

European Medicine Agency 30 Churchill Pl, Canary Wharf, London E14 5EU, UK ,

Get notified the next time we write about European Medicine Agency!